Featured Oncology NewsExperimental Drug Helps Women With Deadly Type of Breast Cancer
February 21, 2019
Merck Scooping Up Cancer Drug Developer Immune Design for $300M
February 21, 2019
Johnson & Johnson Says It’s Been Subpoenaed By SEC, Justice Department
February 21, 2019
Original articles, thought leader interviews, and other resources covering testing, patient selection and treatment options in AML.
Supported by:
Peer-Spectives is a new podcast series that is moderated by our editor-in-chief Robert Figlin, MD, and
features select thought-leaders covering the latest clinical developments in a wide range of cancer settings.
Moderated by:
Steven Spielberg Family
Chair in Hematology-Oncology
Cedars-Sinai Medical Center
We explore the scope of the escalating cost of cancer care, discuss the factors that contribute to the total cost of cancer care,
and provide resources to help us all understand the facts regarding the cost of cancer care.
Sponsored by:
Stemming from the user preference that you set, stay informed and increase your productivity via 27/7 web based access to Ontellitrac and a customized email alert system summarizing the most recent oncology-specific information available.
The Oncology Business Dynamics Learning Platform addresses the need to have a high level of understanding of the non-clinical issues that are influencing the decision making process for hem/oncs today.
ASCO-GU – Bristol’s Renal Cancer Lead Looks to be Short-Lived
GSK Pays Up To $4.2 Billion For Merck KGaA Cancer Immunotherapy
On Immunotherapy Trial, Long-Term Survivors Of Deadly Skin Cancer Point To A Hopeful Future
OBR Finance tracks the market performance of oncology companies and products, and compares our performance versus other indices ...
OBR Radar is a snapshot of upcoming pivotal events in the oncology industry such as FDA action dates, anticipated announcement of pivotal clinical data, and ODAC dates ...
Washington, DC
Orlando, FL
Atlanta, GA
Orlando, FL
Geneva, Switzerland
Denver, CO
Chicago, IL
RAI Amsterdam, The Netherlands
Lugano, Switzerland
San Francisco, CA
Buenos Aires, Argentina
Orlando, FL
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.
Featured Content
Previous
News Story Commentary
Meet the Editorial BoardView all Commentary
Merck's Keytruda Fails Late-Stage Study In Liver Can...
February 20th 2019 by Howard S. Hochster, MD
Another example of Immunotherapy in GI cancer not living up to the expectations (and hype). Despit...
Read More
NRG Oncology Trial Affirms Hypofractionated Radiothe...
February 19th 2019 by Howard Sandler, MD, MS, FASTRO
New guidelines from ASTRO-ASCO recommend moderately hypofractionated radiotherapy for many men with...
Read More
Phase II Trial Shows Novel, Radiolabeled PSMA-Target...
February 13th 2019 by Tomasz M. Beer, MD, FACP
As contemporary hormonal agents are increasingly used earlier in prostate cancer, the need for nove...
Read More
FDA Alerts More Doctors Of Rare Cancer With Breast I...
February 11th 2019 by William McGivney, PhD
Breast Implants; Déjà Vu All Over Again Last week’s FDA warning regarding the association of...
Read More
The Patient Had Bone Cancer. The Diagnosis Arrived 2...
February 08th 2019 by H. Jack West, MD
"Paleo pathology" is cool. Cancer goes back to the Triassic period.
Read More
Bayer to Showcase New Data from its Growing Cancer P...
February 05th 2019 by Tomasz M. Beer, MD, FACP
Daralutamide would be the third agent with demonstrated efficacy in non-metastatic castration resis...
Read More
OBR Green